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The effects of resveratrol 
on the expression of VEGF, TGF‑β, 
and MMP‑9 in endometrial stromal 
cells of women with endometriosis
Tahereh Arablou1, Naheed Aryaeian1, Sepideh Khodaverdi2, Roya Kolahdouz‑Mohammadi1, 
Zahra Moradi3, Nesa Rashidi3 & Ali‑Akbar Delbandi3,4*
Resveratrol is a phytochemical with anti‑angiogenic, anti‑inflammatory, and antioxidant properties. 
The present study has evaluated the effect of resveratrol on the expression of vascular endothelial 
growth factor (VEGF), transforming growth factor‑β (TGF‑β) and matrix metalloproteinase‑9 (MMP‑
9) as factors related to endometriosis progression. Thirteen eutopic (EuESCs) and 8 ectopic (EESCs) 
endometrial stromal cells from women with endometriosis and 11 control endometrial stromal cells 
(CESCs) were treated with resveratrol (100 µM) for 6, 24 and 48 h. The gene and protein expression 
levels of VEGF, TGF‑β, and MMP‑9 were measured using real‑time PCR and ELISA methods, 
respectively. Results showed that the basal gene and protein expression of VEGF and MMP‑9 
were higher in EESCs compared to EuESCs and CESCs (P < 0.01 to  < 0.001 and P < 0.05 to  < 0.01 
respectively). Also, resveratrol treatment decreased the gene and protein expression of VEGF and 
MMP‑9 in EuESCs, EESCs and CESCs (P < 0.05 to  < 0.01 and P < 0.05 to  < 0.01 respectively) and gene 
and protein expression of TGF‑β in EESCs and EuESCs (P < 0.05 to  < 0.01). The effect of resveratrol in 
reduction of VEGF gene expression was statistically more noticeable in EESCs compared to EuESCs 
and CESCs (P < 0.05). According to the findings, resveratrol may ameliorate endometriosis progression 
through reducing the expression of VEGF, TGF‑β, and MMP‑9 in endometrial stromal cells (ESCs).
Abbreviations
VEGF  Vascular endothelial growth factor
TGF-β  Transforming growth factor-β
MMP-9  Matrix metalloproteinase-9
ESCs  Endometrial stromal cells
EuESCs  Eutopic endometrial stromal cells
EESCs  Ectopic endometrial stromal cells
CESCs  Control endometrial stromal cells
EM  Endometriosis
PF  Peritoneal fluid
GnRH  Gonadotropin-releasing hormone
LMP  Last menstrual period
DMEM  Dulbecco’s modified Eagle’s medium
LPS  Lipopolysaccharide
RT-PCR  Reverse transcription polymerase chain reaction
ELISA  Enzyme-linked immunoassay
PCR  Polymerase chain reaction
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase
NF-κB  Nuclear factor-κB
MAP-kinase  Mitogen-activated protein kinase
ACE-I  Angiotensin-converting-enzyme inhibitors
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ROS  Reactive oxygen species
RNS  Reactive nitrogen species
AP-1  Activator protein 1
Phytochemicals are a large group of biologically active compounds found in  plants1. Intake of dietary phyto-
chemicals has been associated with health benefits and disease  prevention2.
Resveratrol is a polyphenolic phytochemical belongs to the stilbenoid  class3. Its main sources are grapes, 
berries, peanuts, and some other  plants4. In recent decades, resveratrol is considered because of its beneficiary 
effects on oxidative  stress5,  inflammation3, tumor  progression6, aging and  angiogenesis7.
Endometriosis (EM), one of the most prevalent gynecological disorders, is characterized by the growth 
of endometrial stroma and glands outside the uterine  cavity8. Its main symptoms are chronic pelvic pain and 
 infertility9. To date, several theories have tried to explain the pathogenesis of the disease; among them, Sampson’s 
retrograde menstruation theory is more  reputable10. This theory stated that translocation of the endometrial 
cells into the peritoneal cavity through fallopian tubes leads to their adhesion, angiogenesis, and growth in the 
peritoneum and formation of the ectopic  lesions10,11. So, according to this theory, growth and angiogenesis fac-
tors play vital roles in disease progression.
Vascular endothelial growth factor (VEGF) is shown to play a crucial role in angiogenesis in peritoneal 
endometriosis. It is secreted by the eutopic endometrium, ectopic endometriotic tissue, and peritoneal fluid 
(PF)  macrophages12,13. Previous studies reported the higher concentration of VEGF in PF from patients with 
endometriosis compared to non-endometriotic controls and its correlation with disease  stages14,15.
Transforming growth factor-β (TGF-β) is one of the most potent growth factors and monocytes chemoattract-
ants. It can induce fibrosis and angiogenesis in ectopic implants and causes endometriosis  progression16,17. The 
PF of women with stage III and IV of endometriosis has higher levels of TGF-β compared to women with milder 
endometriosis, and a significant decrease in concentrations was achieved after treatment with a gonadotropin-
releasing hormone (GnRH)  agonist18.
Matrix metalloproteinase-9 (MMP-9) is a member of proteinases that plays an essential role in the remod-
eling of the extracellular  matrix19. The overexpression of MMP-9 in ectopic endometrial lesions primary seems 
to exacerbate the angiogenesis and invasion of ectopic  implants20,21.
It was claimed that resveratrol could ameliorate endometriosis  progression22. Its effect is due to suppression 
the expression of growth  factors23, decrease cell  proliferation24, reduction of the size of the ectopic  implant25, 
induction of  apoptosis26, reduction of the  inflammation25 and oxidative  stress27, and inhibition the invasion, 
adhesion, and angiogenesis of endometriotic ectopic  lesions22. Also, Resveratrol has shown to suppress the 
expression of VEGF and MMP-9 in rat-induced  endometriosis25 and decrease the expression of VEGF, TGF-β, 
and MMP-9 in other  diseases28–30.
Considering the importance of VEGF, TGF-β and MMP-9 in the development of EM and the inhibitory 
effect of resveratrol on the expression of these factors in other cell types in different diseases, and given that to 
date no study has been performed on the effect of resveratrol on gene and protein expression of these factors in 
ESCs, the aim of the present study was to investigate the effect of resveratrol treatment on the gene and protein 
expression of VEGF, TGF-β and MMP-9 in ectopic (EESCs) and eutopic (EuESCs) endometrial stromal cells in 
women with endometriosis in comparison with non-endometriotic controls (CESCs).
Materials and methods
Study population. The present study was performed on 40 patients with peritoneal endometriosis and 
15 non-endometriotic controls. The inclusion criteria were: being at reproductive age (19–45 years old), at the 
proliferative phase of the menstrual cycle, the III-IV stages of peritoneal endometriosis according to the revised 
American Fertility Society system (rAFS)31 for patients and non-endometriotic lesions for control group based 
on the laparoscopy. The control group was undergone laparoscopy for diagnostic reasons and because of benign 
gynecological problems.
The exclusion criteria were: any history of malignancy, autoimmune or metabolic disorders, taking any hor-
monal medications or dietary supplements within the last three months before the surgery, pregnancy, lactation, 
and cigarette smoking.
All individuals signed written informed consent before participating in the study, and all participants’ privacy 
was respected. The study protocols was approved by the Ethics Committee for Medical Research of Iran Uni-
versity of Medical Sciences (Code: IR.IUMS.rec.1395.9221324203). All methods were performed in accordance 
with the relevant guidelines and regulations.
Sample collection. All sample collection and tissue extraction details were explained  earlier23. Ectopic 
and eutopic endometrial samples were collected using laparoscopic sampling and biopsy curette, respectively. 
All endometriotic cysts (endometrioma) size were ≥ 5 cm in diameter. Tissue samples were put in sterile tubes 
containing Dulbecco’s modified Eagle’s medium (DMEM)-F12 (Sigma-Aldrich, St. Louis, MO, USA) culture 
medium with 1% Penicillin–Streptomycin antibiotics (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) 
and quickly transferred to the laboratory on ice. A part of all samples was taken to the pathology laboratory to 
confirm endometriosis. The phase of the menstrual cycle was confirmed by the histological dating of ectopic 
endometrial implants. In the case of virgins and other patients with only the ectopic tissue, the confirmation of 
the cycle phase done by the last menstrual period (LMP).
Isolation, culture and purification of endometrial stromal cells (ESCs). The digestion of endome-
trial tissue samples and the purification and culture of stromal cells performed as we described  earlier23. Briefly, 
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in the sterile condition, ectopic and eutopic endometrial tissues from endometriotic women and normal endo-
metrial tissues from the control women were minced into smaller pieces and digested in the presence of 2 mg/
ml Collagenase A (Roche, Pleasanton, CA, USA) and 300 mg/ml DNase (Roche, Pleasanton, CA, USA). Then 
the obtained cells were cultured in T25 culture flasks (SPL Life Sciences, Korea), ans stored in an atmosphere 
of 5% CO2 at 37 °C in DMEM-F12 (Sigma-Aldrich, St. Louis, MO, USA) containing 1% Penicillin–Strepto-
mycin antibiotics (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 10% fetal bovine serum (FBS) 
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and adherent stromal cells were allowed to multiply. The 
cultured cells were passaged three times and when they reached to about 80% confluency they were used for 
the treatment. Some tissue samples especially ectopic tissues were excluded due to the cultural contamination, 
inproper pathology results, or not obtained the desired cells. At the end, from 40 endometriotic and 15 non-
endometriotic control tissues, 8 ectopic, 13 eutopic, and 11 control tissues were treated. The purification of the 
ESCs was approved by immunofluorescent staining and flow cytometry. These cells were characterized as a panel 
of  vimentin+,  nestin+,  cytokeratin−,  CD10+,  CD44+,  CD73+,  CD105+,  CD34−, and  CD45− cells. as we described 
 earlier23.
Treatment of endometrial stromal cells with resveratrol. Based on the results of MTT test and the 
pilot  study23, all ESCs from the three study groups were seeded 30 ×  104 in 24-well plates (SPL Life Sciences, 
Korea) to have confluency about 80% for resveratrol treatment. After 3 h treated with the pre-determined opti-
mized concentration of 100 µM resveratrol (Sigma-Aldrich, St. Louis, MO, USA) and stimulated with 100 ng/
ml Lipopolysaccharide (LPS) (Sigma-Aldrich, St. Louis, MO, USA)32, and incubated for three-time points 6, 24 
and 48 h.
Extraction of RNA and quantitative real‑time PCR. For RNA isolation all ESCs were stored in Tri-
zol (Qiagen, Hilden, Germany) at −80  °C. Total RNA was isolated according to the manufacturer’s instruc-
tions. Extracted RNA was reverse transcribed to complementary DNA (cDNA) using reverse transcription-
polymerase chain reaction (RT-PCR) kit (Fermentas, Thermo Fisher Scientific, Waltham, MA, USA). The gene 
expressions of VEGF, TGF-β, and MMP-9 were quantified by real-time PCR with Syber premix Extaq (Biofact, 
Daejeon, Korea) according to the protocol by Rotor-Gene Q (Qiagen, Hilden, Germany). The gene expressions 
were normalized using Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA as an internal control. 
The primer pairs and the size of the amplicons are shown in Table 1. The PCR conditions were mentioned in 
details  earlier23. It included a holding step on 95° for 15 min (for enzyme activation), which followed by 40 cycles 
of 95 °C for the 20 s, extension at 60 °C for 40 s (GAPDH at 58 °C for 40 s) and the melting step at 60° to 99°. All 
reactions were run in duplicate.
Measurement of VEGF, TGF‑β, and MMP‑9 protein. The concentration of VEGF, TGF-β, and MMP-9 
protein in the cell supernatant was examined by a standard enzyme-linked immunoassay (ELISA) kit (Duoset; 
R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol.
Statistical analysis. Statistical analyses were carried out using GraphPad Prism software 6.01 (GraphPad 
Software. Inc). Based on the results of the Kolmogorov–Smirnov test, all data was analyzed using the non-par-
ametric tests, including the Wilcoxon sign-ranked test, Mann–Whitney, and Kruskal–Wallis tests. For the gene 
expression analysis, the fold change and relative expression were compared by calculating the  2−∆Δct and  2−∆ct, 
respectively. P-value < 0.05 was considered as the statistically significant level.
Results
The Basal expression of VEGF gene and protein in ESCs. Based on the results of real-time PCR, 
the VEGF gene was expressed significantly more in EESCs compared to EuESCs and CESCs (Both P < 0.01) in 
the basic state (Fig. 1a). Moreover, according to the results of ELISA, the VEGF protein had significantly higher 
expression in EESCs compared to EuESCs and CESCs (P < 0.01 and P < 0.001 respectively) (Fig. 1b).
Table 1.  The VEGF, TGF-β, MMP-9 and GAPDH primers sequences. IGF-1: Insulin-like growth factor-1; 
HGF: Hepatocyte growth factor; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; bp: Base pair.
Sequence Name Accession No Sequence 5′ to 3’ Amplicon Size (bp)
VEGF-Sense NM_001204384.1
NM_001171622.1
TTG CCT TGC TGC TCT ACC TCCA 
126
VEGF-Anti-sense GAT GGC AGT AGC TGC GCT GATA 
TGF-β-Sense NM_000660.6
XM_011527242.2
TGG TGG AAA CCC ACA ACG AA
113
TGF-β-Anti-sense GAG CAA CAC GGG TTC AGG TA
MMP-9-Sense
NM_004994.2
GCA CGA CGT CTT CCA GTA CC
124
MMP-9- Anti-sense CAG GAT GTC ATA GGT CAC GTAGC 
GAPDH- Sense NM_001289745.2
NM_002046.6
GCA CCG TCA AGG CTG AGA AC
138
GAPDH—Anti-sense TGG TGA AGA CGC CAG TGG A
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The Basal expression of TGF‑β gene and protein in ESCs. According to the results of real-time PCR 
and ELISA the basal gene and protein expression of TGF-β had no statistically significant differences among 
EESCs, EuESCs and CESCs (Fig. 1c,d).
Figure 1.  The basal expression levels of VEGF, TGF-β and MMP-9 genes and proteins in ESCs. The basal 
expression of VEGF, TGF-β and MMP-9 genes and proteins were measured in EESCs (n = 8) and EuESCs 
(n = 13) from endometriotic women and CESCs from non-endometriotic controls (n = 11) by real-time PCR 
and ELISA. (a) The basal expression of VEGF gene, (b) The basal expression of VEGF protein, (c) The basal 
expression of TGF-β gene, (d) The basal expression of TGF-β protein, (e) The basal expression of MMP-9 gene, 
(f) The basal expression of MMP-9 protein. *P-value < 0.05, ** P-value < 0.01 and *** P-value < 0.001 by non-
parametric tests. VEGF: Vascular endothelial growth factor, TGF-β: Transforming growth factor-β, MMP-9: 
Matrix metalloproteinase-9, ESCs: Endometrial stromal cells, EuESCs: Eutopic endometrial stromal cells, 
EESCs: Ectopic endometrial stromal cells, CESCs: Control endometrial stromal cells.
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The Basal expression of MMP‑9 gene and protein in ESCs. Analysis of real-time PCR and ELISA 
methods revealed that the basal expression of MMP-9 gene and protein was significantly more in EESCs in com-
parison with EuESCs (Both gene and protein P < 0.05) and CESCs (Both gene and protein P < 0.01) (Fig. 1e,f).
Resveratrol decreased the expression of VEGF gene in all ESCs. The real-time PCR method dem-
onstrated that treatment with resveratrol (100 µM) reduced the expression of VEGF gene significantly in EESCs 
at 24 (P < 0.05) and 48 h (P < 0.01) and in EuESCs and CESCs only at 48 h (Both P < 0.05) (Table 2). Also, the 
effect of 100 µM resveratrol treatment was more noticeable in EESCs in comparison with EuESCs and CESCs at 
48 h (Both P < 0.05) (Supplementary file).
Resveratrol decreased the expression of TGF‑β gene in EuESCs and EESCs. The TGF-β gene 
expression had significant reduction by treatment with resveratrol (100  µM) in EuESCs and EESCs at 48  h 
(P < 0.05 and P = 0.01 respectively). The TGF-β gene expression had no significant changes in EuESCs and EESCs 
at 6 and 24 h, and in CESCs at all three time intervals (Table 2). There was no significant difference in the effect 
of resveratrol treatment between EESCs and EuESCs at 48 h (Supplementary file).
Resveratrol decreased the expression of MMP‑9 gene in all ESCs. The MMP-9 gene expression was 
significantly reduced by resveratrol (100 µM) in EuESCs at 24 (P < 0.01) and 48 h (P < 0.05) and in EESCs and 
CESCs at 48 h (Both P < 0.05). The gene expression of MMP-9 did not show significant changes in EuESCs at 6 h, 
and in EESCs and CESCs at 6 and 24 h (Table 2). In addition, resveratrol had a greater effect on EESCs compared 
with EuESCs and CESCs at 48 h, but this was not statistically significant (Supplementary file).
Resveratrol decreased the expression of VEGF protein in EuESCs and EESCs. The use of ELISA 
method revealed that the protein expression of VEGF was significantly reduced in EuESCs and EESCs at 48 h by 
Table 2.  The effect of resveratrol on VEGF, TGF-β and MMP-9 gene expression in ESCs. ESCs from 
endometriotic women (8 EESCs and 13 EuESCs) and non-endometriotic controls (11 CESCs) were cultured 
with or without 100 µM resveratrol. After 6, 24, and 48 h, the gene expression of VEGF, TGF-β and MMP-9 
were examined using real-time PCR. Data were analyzed by non-parametric tests. *P-value < 0.05 is statistically 
significant. VEGF: Vascular endothelial growth factor, TGF-β: Transforming growth factor-β, MMP-9: Matrix 
metalloproteinase-9, ESCs: Endometrial stromal cells, EuESCs: Eutopic endometrial stromal cells, EESCs: 
Ectopic endometrial stromal cells, CESCs: Control endometrial stromal cells.
Gene ESC type Treatment time Fold change P-value
VEGF
EuESCs
6 h 0.79 vs 1 0.67
24 h 0.93 vs 1 0.78
48 h 0.44 vs 1 0.04*
EESCs
6 h 0.50 vs 1 0.07
24 h 0.45 vs 1 0.04*
48 h 0.19 vs 1 0.007*
CESCs
6 h 0.99 vs 1 0.64
24 h 0.72 vs 1 0.99
48 h 0.43 vs 1 0.04*
TGF-β
EuESCs
6 h 1.20 vs 1 0.12
24 h 1.36 vs 1 0.10
48 h 0.63 vs 1 0.02*
EESCs
6 h 0.87 vs 1 0.46
24 h 0.55 vs 1 0.15
48 h 0.63 vs 1 0.01*
CESCs
6 h 1.03 vs 1 0.25
24 h 1.20 vs 1 0.25
48 h 1.15 vs 1 0.32
MMP-9
EuESCs
6 h 0.53 vs 1 0.49
24 h 0.20 vs 1 0.002*
48 h 0.58 vs 1 0.04*
EESCs
6 h 0.93 vs 1 0.84
24 h 1.81 vs 1 0.43
48 h 0.08 vs 1 0.03*
CESCs
6 h 0.49 vs 1 0.15
24 h 1.42 vs 1 0.25
48 h 0.27 vs 1 0.03*
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100 µM resveratrol (P < 0.05 and P < 0.01 respectively). Resveratrol treatment had no significant effect at 6 and 
24 h in these cells. The VEGF protein expression did not change significantly in CESCs at any of the treatment 
times (Fig. 2). Although, the effect of resveratrol treatment on reducing VEGF protein expression in EESCs was 
greater than that of EuESCs, this difference was not statistically significant. (Supplementary file).
Resveratrol decreased the expression of TGF‑β protein in EuESCs and EESCs. The effect of 
treatment with 100 µM resveratrol on the expression of TGF-β protein was the same as its gene expression. Res-
veratrol could reduce the expression of this factor in EuESCs and EESCs at 48 (Both P < 0.05). The expression of 
TGF-β protein showed no significant changes at 6 and 24 h in EuESCs and EESCs, and at any treatment times 
in CESCs (Fig. 3). The effect of resveratrol treatment between EESCs and EuESCs had no significant difference 
at 48 h (Supplementary file).
Resveratrol decreased the expression of MMP‑9 in all ESCs. Resveratrol (100 µM) decreased sig-
nificantly the MMP-9 protein in EuESCs, at 24 and 48 h and in EESCs and CESCs at 48 h (All P < 0.05). The 
MMP-9 protein production had no significant changes at 6 in EuESCs at 6 and 24 h in EESCs and CESCs (Fig. 4). 
In addition, the effect of treatment with 100 µM resveratrol at 48 h on the reduction of MMP-9 protein produc-
tion was not statistically significant among three groups (Supplementary file).
Figure 2.  Resveratrol Decreased the Expression of VEGF Protein in EuESCs and EESCs. ESCs from 
endometriotic women (8 EESCs and 13 EuESCs) and non-endometriotic controls (11 CESCs) were cultured 
with or without of 100 µM resveratrol. After 6, 24, and 48 h, the protein expression of VEGF was examined 
using ELISA. (a) 6 hr (Res + vs Res-), (b) 24 hr (Res + vs Res-), (c) 48 hr (Res + vs Res-). *P-value < 0.05, ** 
P-value < 0.01 by non-parametric tests. VEGF: Vascular endothelial growth factor, EuESCs: Eutopic endometrial 
stromal cells, EESCs: Ectopic endometrial stromal cells, CESCs: Control endometrial stromal cells.
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Discussion
The results revealed that the basal expression of VEGF and MMP-9, but not TGF-β in EESCs were significantly 
higher compared to EuESCs and CESCs. To date, some studies assessed the concentration of these factors in PF 
or endometrial implants of the endometriotic  patients21,33–35 and according to our knowledge, the present study 
is the first to compare the expression of VEGF, TGF-β and MMP-9 in EESCs, EuESCs, and CESCs.
The findings of the previous studies, consistent with the present study, have shown that VEGF expression in 
endometrial tissue and PF of patients with endometriosis is increased compared to controls, although, it does not 
differ significantly between the different stages of the  disease33,36. In the only discordant study, the VEGF concen-
tration in PF of patients with genital endometriosis and healthy control women was not significantly  different34. 
VEGF receptors gene expression was also higher in ectopic endometrial lesions than in eutopic  tissue21,37.
VEGF is one of the most important angiogenic factors in endometriosis. It can increase cell proliferation, 
cell migration, and vascular  permeability13,38. The most important cells secreting this factor in endometriosis are 
eutopic and ectopic stromal cells, peritoneal macrophages, and neutrophils that increase the expression of this 
factor in response to elevated inflammatory  conditions13. Increased levels of reactive oxygen species (ROS) due to 
oxidative stress in endometriosis can also increase VEGF expression and its angiogenesis in in-vivo and in-vitro39.
The few studies that have examined the expression of TGF-β in endometriosis have shown contradictory 
findings. For example, in a study of Sokolov et al. the concentration of TGF-β in PF did not differ significantly 
between the women with genital endometriosis and healthy  controls34, but two other studies, showed that levels 
of TGF-β in serum and PF were higher in patients than in controls, and this level, especially in PF, increased 
with increasing severity of the  disease35,40.
Figure 3.  Resveratrol Decreased the Expression of TGF-β Protein in EuESCs and EESCs. ESCs from 
endometriotic women (8 EESCs and 13 EuESCs) and non-endometriotic controls (11 CESCs) were cultured 
with or without of 100 µM resveratrol. After 6, 24, and 48 h, the protein expression of TGF-β was examined 
using ELISA. (a) 6 hr (Res + vs Res-), (b) 24 hr (Res + vs Res-), (c) 48 hr (Res + vs Res-). *P-value < 0.05 by non-
parametric tests. TGF-β: Transforming growth factor-β, EuESCs: Eutopic endometrial stromal cells, EESCs: 
Ectopic endometrial stromal cells, CESCs: Control endometrial stromal cells.
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Several studies have shown the role of TGF-β in regulating the immune system and  inflammation41. TGF-β 
enhances the growth and angiogenesis of ESCs, especially ectopic cells, and plays an essential role in the develop-
ment of endometriotic  lesions13. Increased expression of this factor in endometriosis seems to occur in response 
to increased inflammatory conditions and oxidative stress in the peritoneal  cavity42. As is evident in our study, 
there was no significant difference in TGF-β expression in the stromal cells of the study groups. Previous studies 
reported that peritoneal mesothelial cells are the most important source of this factor in peritoneum-related dis-
eases such as peritoneal endometriosis, followed by peritoneal macrophages, ectopic endometrial tissue including 
 ESCs17, it appears that the increased expression of this factor in the serum and PF of patients with endometriosis 
than in controls has been reported in some previous  studies35,40, may be due to the increased production of this 
cytokine by peritoneal mesothelial cells and then other sources and in the meantime, the ESCs evaluated in the 
present study, have less role in the production of this factor. Previous studies have also shown that the concentra-
tion of TGF-β in the peritoneum of individuals with endometriosis changes during the menstrual cycle and its 
highest concentration is seen in the secretory phase and in the premenstrual  phase18,41. However, in our study, 
we measured the expression of TGF-β in the proliferative phase.
In the case of MMP-9, the only study comparing the expression of this factor in ectopic endometrial lesions 
with eutopic endometrium is Machado’s study on an induced model of endometriosis in rats and reported find-
ings consistent with the present  study21.
Studies have shown that chronic inflammation increases MMP-9 expression. Expression of MMP-9 by EESCs 
and EuESCs increases in endometriosis in response to inflammatory conditions in the peritoneal cavity, which 
is higher in ectopic than eutopic lesions and activation of the NF-κB and MAP-kinase signaling and other 
Figure 4.  Resveratrol Decreased the Expression of MMP-9 Protein in all ESCs. ESCs from endometriotic 
women (8 EESCs and 13 EuESCs) and non-endometriotic controls (11 CESCs) were cultured with or without of 
100 µM resveratrol. After 6, 24, and 48 h, the protein expression of MMP-9 was examined using ELISA. (a) 6 hr 
(Res + vs Res-), (b) 24 hr (Res + vs Res-), (c) 48 hr (Res + vs Res-). *P-value < 0.05 by non-parametric tests. MMP-
9: Matrix metalloproteinase-9, EuESCs: Eutopic endometrial stromal cells, EESCs: Ectopic endometrial stromal 
cells, CESCs: Control endometrial stromal cells.
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inflammatory pathways, as well as to increased oxidative  stress43,44; This assists the replacement, growth, and 
invasion of endometriotic  implants20,21. Increased production and activity of MMP-9 increase the degradation 
and regeneration of extracellular matrix, angiogenesis, and VEGF  secretion19,45.
The present study revealed that the gene and protein expression of VEGF, TGF-β, and MMP-9 in EESCs and 
EuESCs were reduced by resveratrol treatment. According to our knowledge, this is the first study to investigate 
the effect of resveratrol on VEGF expression in ESCs of patients with endometriosis. In the only animal study, 
resveratrol significantly reduced VEGF expression in endometriosis-induced  rats25. Other previous in-vivo and 
in-vitro studies on the effect of resveratrol on VEGF expression in other diseases have also reported findings 
consistent with the present  study29,46–49.
The mechanisms of the effect of resveratrol on VEGF expression seems to be through activation of the sir-
tuin-1 molecule and inhibition of the NF-κB  pathway50. Resveratrol can also inhibit VEGF through ACE-I-like 
activity. Thus, resveratrol inhibits positive feedback between angiotensin-II and VEGF. The in-vitro studies have 
shown that ACE-I-like factors can inhibit VEGF-induced endothelial cell migration and invasion and inhibit 
VEGF mRNA  expression49,51. Resveratrol may also block the VEGF receptor response pathway by reducing 
MAP-kinase phosphorylation and inhibiting VEGF-induced angiogenesis by blocking tyrosine phosphorylation 
in the cadherin  molecule46. Besides, resveratrol reduces VEGF expression and its invasion and angiogenesis by 
preventing the production and eliminating the ROS and reactive nitrogen species (RNS)39,52.
It seems that the difference in the effect of resveratrol on the reduction of VEGF gene expression in EESCs 
compared to EuESCs and CESCs is due to differences in inflammatory and micro-environmental conditions 
of these cells. Previous studies have shown that EESCs, EuESCs, and CESCs differ in cytokine expression, cell 
proliferation, invasion, metastasis, and response to nutritional  interventions53,54.
The present study is the first to investigate the effect of resveratrol on TGF-β expression in ESCs of patients 
with endometriosis, and it is not possible to compare the results with similar studies. Therefore, the findings 
of this study were compared with those of animal studies on the effect of resveratrol on TGF-β levels in other 
diseases. Most of these studies consistent with the present study have shown that resveratrol can decrease TGF-β 
gene and protein  expression28,55,56. In the only inconsistent study, a single-dose intraperitoneal injection of res-
veratrol had no significant effect on TGF-β levels in rats with acute liver injury, possibly due to the amount and 
timing of the  intervention57.
Resveratrol has been reported to inhibit TGF-β transcription by blocking the NF-κB  pathway55. Resveratrol 
can also reduce TGF-β expression by blocking the activator protein 1 (AP-1) molecule and removing ROS and 
reducing oxidative  stress58. Resveratrol also down-regulates TGF-β expression and activity by down-regulating 
TGF-β signaling pathway molecules, including, Smad-2, 3,459. TGF-β is a pro-fibrotic factor that can increase 
the production of type IV collagen and  fibrin28. Resveratrol treatment can prevent TGF-β-induced fibrotic tissue 
growth in ectopic  lesions55.
The present study is the first to assess the effect of resveratrol treatment on MMP-9 expression in ESCs. The 
only animal study that investigated the effect of resveratrol on MMP-9 expression in endometriosis also reported 
the same  results25. Other in-vivo and in-vitro studies also shown that resveratrol decreases MMP-9 mRNA and 
protein expression and suppresses the activity of this  enzyme30,60,61. In the only inconsistent study, Gweon and 
Kim reported that resveratrol at different concentrations increased the activity and expression of MMP-9 in 
human fibrosarcoma cells. The cause of this contradictory finding may be the different inflammatory  condition62.
MMP-9 is one of the proteins whose expression is enhanced by activation of the NF-κB pathway. It appears 
that resveratrol decreases the expression of this factor by suppressing the expression and activity of the NF-κB 
 pathway60. Resveratrol inhibits NF-κB transcriptional activity by blocking phosphorylation and degradation of 
the IκB inhibitor molecule, thereby inhibiting NF-κB translocation and DNA binding and preventing expression 
of inflammatory cytokines and growth factors and angiogenesis including MMP-963. Resveratrol can also prevent 
MMP-9 expression by decreasing TGF-β expression, inhibiting MAP-kinase signaling pathway, reabsorption of 
ROS, and reducing oxidative  stress64,65.
The present study had some advantages and limitations: As we mentioned earlier, it was the first study 
investigated the basal gene and protein expression and also the effect of resverstrol treatment on the gene and 
protein expression of VEGF, TGF-β and MMP-9 in ectopic (EESCs), and eutopic (EuESCs) endometrial stro-
mal cells of women with endometriosis in comparison with non-endometriotic controls (CESCs). One of the 
limitations was that the present study was carried out only in the severe (III and IV) stages of the EM and at 
the proliferative phase. Also, it would have been better if we could assess the MMP-9 activity. It is also better to 
investigate the effect of resveratrol treatment on the expression of VEGF, TGF-β and MMP-9 in the peritoneal 
fluid mononuclear cells (PFMCs) and mesothelial cells as the important sources of these factors. Moreover, in 
order to better determine the effect of resveratrol on EM, further studies are needed on the effect of resveratrol 
treatment on cell proliferation, angiogenesis, invasion, adhesion, apoptosis, and other processes involved in the 
pathogenesis of EM.
Conclusion
The present study showed that the basal gene and protein expression of VEGF and MMP-9 were higher in EESCs 
compared to EuESCs and CESCs. The treatment of EESCs and EuESCs with resveratrol could reduce the gene and 
protein expression of VEGF, TGF-β, and MMP-9. Further in-vitro and in-vivo studies are needed to determine 
the possible beneficial effects of resveratrol on EM progression.
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